These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 24240115

  • 1. Pertuzumab protects the achilles' heel of trastuzumab--emtansine.
    Gwin WR, Spector NL.
    Clin Cancer Res; 2014 Jan 15; 20(2):278-80. PubMed ID: 24240115
    [Abstract] [Full Text] [Related]

  • 2. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
    Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX.
    Clin Cancer Res; 2014 Jan 15; 20(2):456-68. PubMed ID: 24097864
    [Abstract] [Full Text] [Related]

  • 3. Acquired resistance to trastuzumab/pertuzumab or to T-DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728.
    Irie H, Kawabata R, Fujioka Y, Nakagawa F, Itadani H, Nagase H, Ito K, Uchida J, Ohkubo S, Matsuo K.
    Cancer Sci; 2020 Jun 15; 111(6):2123-2131. PubMed ID: 32248641
    [Abstract] [Full Text] [Related]

  • 4. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA, Cicci TA, Auten JJ, Lowe DK.
    Ann Pharmacother; 2014 Nov 15; 48(11):1484-93. PubMed ID: 25082874
    [Abstract] [Full Text] [Related]

  • 5. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
    Kim SB, Wildiers H, Krop IE, Smitt M, Yu R, Lysbet de Haas S, Gonzalez-Martin A.
    Int J Cancer; 2016 Nov 15; 139(10):2336-42. PubMed ID: 27428671
    [Abstract] [Full Text] [Related]

  • 6. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
    De Mattos-Arruda L, Cortes J.
    Adv Ther; 2013 Jul 15; 30(7):645-58. PubMed ID: 23881722
    [Abstract] [Full Text] [Related]

  • 7. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
    Baron JM, Boster BL, Barnett CM.
    J Oncol Pharm Pract; 2015 Apr 15; 21(2):132-42. PubMed ID: 24682654
    [Abstract] [Full Text] [Related]

  • 8. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
    Yamashita-Kashima Y, Shu S, Harada N, Fujimoto-Ouchi K.
    Oncol Rep; 2013 Sep 15; 30(3):1087-93. PubMed ID: 23783223
    [Abstract] [Full Text] [Related]

  • 9. Emerging strategies for the dual inhibition of HER2-positive breast cancer.
    Konecny GE.
    Curr Opin Obstet Gynecol; 2013 Feb 15; 25(1):55-65. PubMed ID: 23241641
    [Abstract] [Full Text] [Related]

  • 10. Pertuzumab in gastrointestinal cancer.
    Oh DY, Bang YJ.
    Expert Opin Biol Ther; 2016 Feb 15; 16(2):243-53. PubMed ID: 26619359
    [Abstract] [Full Text] [Related]

  • 11. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.
    Doroshow DB, LoRusso PM.
    Future Oncol; 2018 Mar 15; 14(7):589-602. PubMed ID: 29214842
    [Abstract] [Full Text] [Related]

  • 12. Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
    Van den Mooter T, Teuwen LA, Rutten A, Dirix L.
    Expert Opin Biol Ther; 2015 May 15; 15(5):749-60. PubMed ID: 25865453
    [Abstract] [Full Text] [Related]

  • 13. Pertuzumab for the treatment of metastatic breast cancer.
    Langdon SP, Cameron DA.
    Expert Rev Anticancer Ther; 2013 Aug 15; 13(8):907-18. PubMed ID: 23984893
    [Abstract] [Full Text] [Related]

  • 14. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I, Winer EP.
    Clin Cancer Res; 2014 Jan 01; 20(1):15-20. PubMed ID: 24135146
    [Abstract] [Full Text] [Related]

  • 15. Trastuzumab emtansine in breast cancer.
    Dirix LY, Rutten A, Huget P, Dirix M.
    Expert Opin Biol Ther; 2013 Apr 01; 13(4):607-14. PubMed ID: 23477731
    [Abstract] [Full Text] [Related]

  • 16. Pertuzumab: optimizing HER2 blockade.
    Metzger-Filho O, Winer EP, Krop I.
    Clin Cancer Res; 2013 Oct 15; 19(20):5552-6. PubMed ID: 23942091
    [Abstract] [Full Text] [Related]

  • 17. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
    Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K.
    Curr Med Res Opin; 2013 Apr 15; 29(4):405-14. PubMed ID: 23402224
    [Abstract] [Full Text] [Related]

  • 18. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA, Steins A, Fessler E, Stathi P, Lesterhuis WJ, Krishnadath KK, Vermeulen L, Medema JP, Bijlsma MF, van Laarhoven HWM.
    Gastroenterology; 2017 Jul 15; 153(1):63-76.e14. PubMed ID: 28286209
    [Abstract] [Full Text] [Related]

  • 19. Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.
    Haddley K.
    Drugs Today (Barc); 2013 Nov 15; 49(11):701-15. PubMed ID: 24308017
    [Abstract] [Full Text] [Related]

  • 20. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
    Martínez MT, Pérez-Fidalgo JA, Martín-Martorell P, Cejalvo JM, Pons V, Bermejo B, Martín M, Albanell J, Lluch A.
    Crit Rev Oncol Hematol; 2016 Jan 15; 97():96-106. PubMed ID: 26318092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.